Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout

Pfizer (NYSE:PFE) shares rose 2.6% to $24.65 following its announcement to acquire weight-loss drug company Metsera for up to $7.3 billion, marking its best single-day gain since July. This news spurred significant bullish options activity, with call volume quadrupling the intraday average and a 2.72 call/put ratio ranking higher than 82% of annual readings, indicating strong investor optimism. Options traders are also pricing in low future volatility, with the Schaeffer's Volatility Index at the 5th percentile of its annual range.

Analysis

Pfizer's (PFE) stock experienced its best single-day percentage gain since July, rising 2.6% to $24.65, following the announcement of its plan to acquire weight-loss drug company Metsera in a deal valued up to $7.3 billion. This strategic move into the lucrative weight-loss market has been met with significant bullish sentiment from the options market. Call volume surged to 115,000 contracts, four times the intraday average and far outpacing the 17,000 puts traded, with new positions being opened in the October 25 and September 26 24.50 calls. This sentiment is further quantified by the 50-day call/put volume ratio of 2.72, which ranks in the 82nd percentile of its annual range, indicating a historically high level of bullish speculation. Despite this positive momentum, the stock faces a technical resistance ceiling at the $25 level and is still down 16.5% over the last 12 months. Concurrently, the Schaeffer's Volatility Index (SVI) of 23% is in the 5th percentile of its annual range, suggesting that options traders are pricing in low volatility expectations, making options strategies a potentially cost-effective route for expressing a market view.

Key Decisions for Investors

• Given the strong positive market reaction and heavily bullish options positioning on the Metsera acquisition, investors could consider establishing or adding to long positions, potentially using call options which are currently pricing in low implied volatility.
• Traders should closely monitor the stock's performance around the $25 resistance level, as its failure to break this ceiling in late August suggests it could be a significant barrier to further near-term gains.
• While the acquisition is a positive catalyst, investors should weigh this against the stock's 16.5% decline over the past year and assess whether this strategic move is sufficient to reverse the longer-term downtrend.